Currently there are two clinical trials investigating PI3Kβ inhibitor GSK2636771 (NCT02215096) and pan-PI3K/mTOR inhibitor LY3023414 (NCT02407054) in combination with enzalutamide in metastatic castration-resistant prostate cancer patients. The gene discussed is MTOR; the disease is prostate carcinoma.